At a glance
ClinicalIndex Comparison Record- ✓Age 35-69 years at diabetes onset
- ✓No history of ketonuria or diabetic ketoacidosis
- ✓Not requiring insulin for glycemic control
- ✓Currently on ≤2 oral hypoglycemic agents
- ✕History of chronic pancreatitis or other secondary diabetes causes
- ✕Receiving systemic corticosteroids
- ✕Severe systemic illness (recent MI, CHF, cerebrovascular disease)
- ✕Creatinine >1.4 mg/dL or liver enzymes >2× upper limit of normal
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes
In Brief
A clinical study evaluating rosiglitazone and glyburide for Type 2 Diabetes Mellitus. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide.
Study Details
Timeline
Interventions
Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.